Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

计划入组 405 人 · 首次发布于 2005 年 7 月 22 日

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

计划入组 32 人 · 首次发布于 2003 年 1 月 27 日

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

首次发布于 2003 年 1 月 27 日

Peginterferon alfacon-1

Polyethylene glycol(Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave)

Interferon alfa

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

Protalix Biotherapeutics

Israel

FDA Accepts EIT Pharma's NDA for Lonafarnib, First Oral Therapy Candidate for Chronic Hepatitis D

Vir Biotechnology's Tobevibart and Elebsiran Combination Shows Promise in Chronic Hepatitis B Treatment

Vir Biotechnology Announces Positive Results for Tobevibart and Elebsiran Combination Therapy in Chronic Hepatitis B